Last reviewed · How we verify

Intermittent bolus infusion of levobupivacaine

University Hospital, Antwerp · FDA-approved active Small molecule Quality 2/100

Intermittent bolus infusion of levobupivacaine is a Small molecule drug developed by University Hospital, Antwerp. It is currently FDA-approved. Also known as: chirocaine.

At a glance

Generic nameIntermittent bolus infusion of levobupivacaine
Also known aschirocaine
SponsorUniversity Hospital, Antwerp
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intermittent bolus infusion of levobupivacaine

What is Intermittent bolus infusion of levobupivacaine?

Intermittent bolus infusion of levobupivacaine is a Small molecule drug developed by University Hospital, Antwerp.

Who makes Intermittent bolus infusion of levobupivacaine?

Intermittent bolus infusion of levobupivacaine is developed and marketed by University Hospital, Antwerp (see full University Hospital, Antwerp pipeline at /company/university-hospital-antwerp).

Is Intermittent bolus infusion of levobupivacaine also known as anything else?

Intermittent bolus infusion of levobupivacaine is also known as chirocaine.

What development phase is Intermittent bolus infusion of levobupivacaine in?

Intermittent bolus infusion of levobupivacaine is FDA-approved (marketed).

Related